Adding a T-cell receptor to CAR T cells may reduce side effects of immunotherapies designed to target solid tumors.
All in National Cancer Institute
Adding a T-cell receptor to CAR T cells may reduce side effects of immunotherapies designed to target solid tumors.
Aberrant RAS proteins, found in 20 to 30 percent of cancers, can promote the export of proteins from a cell’s nucleus to its cytoplasm, where some can contribute to cancerous growth.
Scientists have a new view of how a dangerous form of DNA damage arises and is repaired in dividing cells.
Waves of regulatory changes can transform self-renewing neuroblastoma cells into neurons.
Immune cells convert an immunosuppressive lipid into an anticancer immunity enhancer.
NCI trial leads to first drug approval for a very rare cancer.
March 2024. Full story at National Cancer Institute.
An immune signal that reprograms fat metabolism could help control nonalcoholic fatty liver disease.
Studies identify a marker of treatment response for patients with advanced, drug-resistant ovarian cancer.
Full story at National Cancer Institute.
Studying osteosarcoma in dogs may improve treatment options for people and pets.